Baird Capital Invests in Blue Matter
CHICAGO/LONDON – Sept. 1, 2020 –Baird Capital, the direct private investment arm of Baird, announced today that its global private equity team has invested in Blue Matter Consulting LLC (“Blue Matter”), a leading strategic consulting firm serving the life sciences industry. Financial details of the deal were not disclosed.
Founded in 2012, Blue Matter provides consultancy services to the global pharmaceutical sector, principally in the areas of product and portfolio strategy, organizational design, and product launch planning and readiness. Blue Matter is a global business with offices in San Francisco, New York, London, Zurich, and Berlin. The company has a wide range of therapeutic expertise, with a deep focus on oncology and rare diseases.
"We are so pleased to bring Blue Matter into the Baird Capital portfolio," said Gordon Pan, President of Baird Capital. "Ashwin and Emily are brilliant partners, and their professional and personal missions are a natural fit with our diverse and tenured group.”
Blue Matter’s international client base includes many of the world’s largest pharmaceutical companies that value their ability to bring real insight to their most critical decisions. Co-Founders and Managing Partners Ashwin Dandekar and Emily Hua have decades of experience in the life sciences and pharmaceutical consulting, with proven track records advising many of the biopharmaceutical industry’s most innovative companies and product teams.
"It was a natural connection when we met Baird Capital and its leadership team,” said Dandekar. "We believe this partnership will accelerate our growth strategy on multiple fronts, helping to drive faster organic growth and expanding our ability to consider strategic acquisitions. We look forward to growing Blue Matter together."
“We’re very excited about this relationship,” added Hua. “Baird Capital’s investment will greatly enhance our ability to invest in our team and do more of what we do best: helping push the boundaries of science and technology to improve people’s lives.”
Blue Matter marks Baird Capital’s fifth private equity investment in 2020. For more information on Baird Capital and its portfolio spanning the technology, industrial and healthcare sectors, visit www.BairdCapital.com.
About Baird Capital
Baird Capital makes venture capital, growth equity and private equity investments in strategically targeted sectors around the world. Having invested in more than 310 companies over its history, Baird Capital partners with entrepreneurs and, leveraging its executive networks, strives to build exceptional companies. Baird Capital provides operational support to its portfolio companies through teams on the ground in the United States, Europe and Asia, a proactive portfolio operations team and a deep network of relationships, which together strive to deliver enhanced shareholder value. Baird Capital is the direct private investment arm of Robert W. Baird & Co. For more information, please visit www.BairdCapital.com.
Baird Capital Partners Europe Limited is authorised and regulated in the United Kingdom by the Financial Conduct Authority.
For additional information, contact:
Baird Public Relations